Atsena Reports LIGHTHOUSE data at ARVO - Poll - MDSpire

Atsena Reports LIGHTHOUSE data at ARVO

Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.

  • May 1, 2025

  • 3 min

Share

Original Source(s)

Atsena Reports LIGHTHOUSE data at ARVO

  • May 1, 2025

Related Content

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

Suspected Ocular Toxoplasmosis in Patients with ABCA4-Related Maculopathy

Survey: 96% of Optometrists Assess Smoking Status

Survey finds widespread smoking status screening among optometrists in Wales following national training requirements.